RFM
TGTX icon

Royal Fund Management’s TG Therapeutics TGTX Stock Holding History

Royal Fund Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 527
2020
Q1 		$0 Hold
1
– – ﹤0.01% 731
2019
Q4 		$0 Hold
1
– – ﹤0.01% 699
2019
Q3 		$0 Hold
1
– – ﹤0.01% 666
2019
Q2 		$0 Hold
1
– – ﹤0.01% 655
2019
Q1 		$0 Hold
1
– – ﹤0.01% 672
2018
Q4 		$0 Hold
1
– – ﹤0.01% 649
2018
Q3 		$0 Hold
1
– – ﹤0.01% 647
2018
Q2 		$0 Hold
1
– – ﹤0.01% 637
2018
Q1 		$0 Hold
1
– – ﹤0.01% 696
2017
Q4 		$0 Hold
1
– – ﹤0.01% 698
2017
Q3 		$0 Hold
1
– – ﹤0.01% 518
2017
Q2 		$0 Hold
1
– – ﹤0.01% 510
2017
Q1 		$0 Hold
1
– – ﹤0.01% 471
2016
Q4 		$0 Buy
+1
New +$6 ﹤0.01% 413

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Royal Fund Management's TGTX Position: Q2 2020 in Review

Royal Fund Management sold out of TG Therapeutics (TGTX) in Q2 2020, closing a stake of 1 share.

Royal Fund Management first reported a position in TGTX in Q4 2016 and held it in 14 quarters. The position peaked at $0 in Q1 2020. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

  • Royal Fund Management reported no remaining TG Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 1 TG Therapeutics share in Q2 2020.
  • Royal Fund Management first reported a position in TG Therapeutics in Q4 2016 and held it in 14 quarters.
  • Royal Fund Management's TG Therapeutics position peaked at $0 in Q1 2020.
  • 175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.